Business Context and Reporting Period
This Form 6-K filing by BiondVax Pharmaceuticals Ltd. (not Scinai Immunotherapeutics Ltd.) covers the month of June 2015, with a specific reporting date of June 25, 2015. The document reports on changes in senior officer holdings following the exercise of an underwriter's over-allotment option in the company's U.S. IPO.
Key Financial Metrics
The filing does not provide revenue, profit, cash flow, margins, debt, or liquidity metrics. The only financial data point disclosed is the quoted share price of US$5.00 on June 24, 2015.
Material Changes
The filing details two specific transactions involving executive officers purchasing American Depositary Shares (ADS) on June 24, 2015:
- Uri Ben Or: Purchased 5,000 ADSs (representing 200,000 ordinary shares). His total holding increased from 0 to 200,000 shares (0.15% of equity).
- Tamar Ben Yedidia: Purchased 5,000 ADSs (representing 200,000 ordinary shares). Her total holding increased from 150,000 to 350,000 shares (0.26% of equity).
Guidance, Outlook, and Risks
The filing contains no management commentary, future guidance, risk factors, or contingencies. It is strictly a regulatory disclosure regarding insider trading activity related to the IPO over-allotment.
Investor Verification Checklist
- Verify the company name is BiondVax Pharmaceuticals Ltd., not Scinai Immunotherapeutics Ltd.
- Confirm the share price of US$5.00 reflects the market value at the time of the officer purchases.
- Review the referenced IPO filing (Reference No. 2015-01-052125) for details on the over-allotment option exercise.
- Note that this filing does not contain operational or financial performance data.